Actavis to Divest Pharmatech to TPG

-- TPG to Focus Company on Growth and Development of Innovative Products --

- Divestiture Allows Actavis to Sharpen Focus on Supporting Existing Global Supply Chain Network -

Feb 13, 2015, 08:30 ET from Actavis plc

DUBLIN and FORT WORTH, Texas, Feb. 13, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) and TPG, the global private investment firm, today announced that they have entered into definitive agreements, under which Actavis will divest to TPG the business currently known as Aptalis Pharmaceutical Technologies (Pharmatech)  — a pharmaceutical outsourcing and R&D business within Actavis' subsidiary Aptalis operating in the United States, Canada and Europe (where the transaction is, in certain jurisdictions, still subject to local regulations, discussions and clearances). No other Aptalis businesses or products are included in the transaction.  No financial terms were disclosed. 

Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO

Pharmatech is a leader in pharmaceutical R&D and manufacturing, with specialized capabilities in areas such as taste-masking and customized drug release and the ability to support projects from formulation through scale-up and commercial-scale manufacturing.  John Fraher, current president of Aptalis Pharmaceutical Technologies, will become CEO of the new standalone company, and will be joined by others from his management team.  The business will continue to operate integrated R&D and manufacturing facilities in North America and Europe.

"Our decision to divest the Pharmatech business is consistent with our strategic commitment to build leadership positions in our core areas of strength," said Robert Stewart, Chief Operating Officer of Actavis.  "It will enable our industry-leading Global Operations team to sharpen their focus on supporting our existing global supply chain, and on preparing for the expansion of our manufacturing network with the addition of the Allergan facilities following the close of the acquisition later this year. The Pharmatech team has done an exceptional job in meeting its objectives, and I would like to thank them for the tremendous work they have done for Actavis.  The decision to divest Pharmatech will have no impact on our commitment to investing in and developing our industry-leading Medis third-party business."

"We see great demand in the market for Pharmatech's drug delivery and R&D expertise, and by launching this platform, we hope to continue to support the growth and innovation of pharmaceutical companies, both through the development of de novo products, novel value-added formulations and targeted generic products," said John Schilling of TPG.

By acquiring Pharmatech TPG intends to use the company as a platform to enter into new partnerships and make additional acquisitions to grow the business.  TPG's healthcare practice has invested approximately $6 billion in equity since 2007, and the firm has executed more than 20 carve-outs from major corporations since its founding.

"We're excited to renew our partnership with TPG, and believe the firm's experience in the pharma industry, combined with their past successes in establishing market-leaders from carve-outs, positions us well  to build a new, successful platform," said John Fraher, president of Aptalis Pharmaceutical Technologies.

The transaction is expected to close by mid-2015, and is subject to customary closing conditions and regulatory approvals.

About Actavis Actavis plc (NYSE: ACT), headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world. 

Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory and anti-infective therapeutic categories.  The company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications.  Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.

For more information, visit Actavis' website at www.actavis.com.

About TPG

TPG is a leading global private investment firm founded in 1992 with $65 billion of assets under management and offices in San Francisco, Fort Worth, Austin, Dallas, Houston, New York, Beijing, Hong Kong, London, Luxembourg, Melbourne, Moscow, Mumbai, São Paulo, Shanghai, Singapore and Tokyo.  TPG has extensive experience with global public and private investments executed through leveraged buyouts, recapitalizations, spinouts, growth investments, joint ventures and restructurings.  With a strong history of executing carve-outs and partnering with blue chip companies, TPG's successful carve-outs include On Semiconductor from Motorola, Burger King from Diageo, Lenovo from IBM, Fenwal from Baxter, Surgical Care Affiliates from HealthSouth, and many others.  In addition to Aptalis, the Firm's healthcare investments have included EnvisionRx, Fenwal, Healthscope, IASIS Healthcare, Immucor, IMS Health, Par Pharmaceutical, Quintiles Transnational and Surgical Care Affiliates, among others. For more information visit www.tpg.com.

Actavis Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Actavis' products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis' Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements.

 CONTACTS:

Actavis:

Investors:

Lisa DeFrancesco

862-261-7152

Media:

Charlie Mayr

862-261-8030

David Belian

862-261-8141

TPG:

Owen Blicksilver Public Relations, Inc.

Lisa Baker

914-725-5949

lisa@blicksilverpr.com

Jennifer Hurson

845-507-0571

jennifer@blicksilverpr.com

 

SOURCE Actavis plc



RELATED LINKS

http://www.actavis.com